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Abstract 
Background: Influenza virus infection is among the most detrimental threats to the health of humans and some 
animals, infecting millions of people annually all around the world and in many thousands of cases giving rise to 
pneumonia and death. All those health crises happen despite previous and recent developments in anti-influenza 
vaccination, suggesting the need for employing more sophisticated methods to control this malign infection.
Main body
The innate immunity modules are at the forefront of combating against influenza infection in the respiratory tract, 
among which, innate T cells, particularly gamma-delta (γδ) T cells, play a critical role in filling the gap needed for 
adaptive immune cells maturation, linking the innate and adaptive immunity together. Upon infection with influenza 
virus, production of cytokines and chemokines including CCL3, CCL4, and CCL5 from respiratory epithelium recruits 
γδ T cells at the site of infection in a CCR5 receptor-dependent fashion. Next, γδ T cells become activated in response 
to influenza virus infection and produce large amounts of proinflammatory cytokines, especially IL-17A. Regardless of 
γδ T cells’ roles in triggering the adaptive arm of the immune system, they also protect the respiratory epithelium by 
cytolytic and non-cytolytic antiviral mechanisms, as well as by enhancing neutrophils and natural killer cells recruit-
ment to the infection site.
Conclusion: In this review, we explored varied strategies of γδ T cells in defense to influenza virus infection and how 
they can potentially provide balanced protective immune responses against infected cells. The results may provide a 
potential window for the incorporation of intact or engineered γδ T cells for developing novel antiviral approaches or 
for immunotherapeutic purposes.
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Background
It has been fully demonstrated that influenza virus infec-
tion is a serious menacing threat to human health, caus-
ing over 50,000 death tolls around the world annually [1]. 
In addition, reassortment of influenza virus genome due 
to antigenic drift and shift leads to pandemic outbreak, 
resulting in severe diseases such as that observed in the 
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1918 pandemic strain with over 50 million deaths during 
2 years [2]. Although annual vaccination is substantially 
considered as an effective strategy against influenza virus 
infection, poor adherence and low efficacy of employed 
influenza vaccine strains increase the demands for better 
understanding of host immune responses [3, 4].
Upon influenza virus infection within the cells, the 
innate compartment of immune system is activated in 
response to detection of pathogen-associated molecu-
lar patterns (PAMPs), specific of viral infection, by pat-
tern recognition receptors (PRRs). Of note, the innate 
immune system employs three distinct groups of PRRs 
for recognition of influenza virus including RLRs (reti-
noic acid-inducible gene-I-like receptors or RIG-I-like 
receptors), NLRs (NOD-like receptors), and TLRs (toll-
like receptors) [5]. This recognition results in the pro-
duction of different cytokines and chemokines such as 
interferons (IFNs), which limits the early viral spread 
and further mediates adaptive immune response [3, 6]. 
Activated innate response bestows the first line of cellu-
lar defense to protect hosts against influenza virus infec-
tion. Each leukocyte such as neutrophils, monocytes, 
natural killer (NK) cells, innate lymphoid cells (ILCs), and 
gamma-delta (γδ) T cells may contribute to anti-influ-
enza protection through varied strategies.
γδ T cells, which based on the usage of either Vδ1 or 
Vδ2 domains are classified into two major subgroups [7, 
8], are important components of both innate and adap-
tive immunity, however, they just constitute approxi-
mately 1–10% of peripheral blood T cells in humans. It 
has been established that γδ T cells not only exert anti-
influenza activity by direct elimination of virus [9, 10], 
but also inhibit virus replication through the secretion of 
IFN-γ [11, 12]. Moreover, a pre-clinical study has shown 
that the proportion of γδ T cells was around 15–30% of 
the lymphocytes in the BAL between 10 to 15 days fol-
lowing infection, suggesting the possible role of this type 
of cell in recovery from influenza infection [13]. Besides, 
a study demonstrated that γδ T cell is required for initia-
tion of effective immune responses and maintenance of 
lung homeostasis in influenza-infected individuals [14]. It 
has been regarded that upon encountering non-peptide 
phosphoantigens, isopentenyl pyrophosphate (IPP) or 
pathogen-associated antigens independent from major 
histocompatibility complex (MHC) presentation, γδ T 
cells become activated, eventually resulting in regula-
tion of immune responses [15, 16]. It is well established 
that γδ T cells are predominantly considered as innate 
immune cells but can develop memory-like adaptive 
responses, bridging the gap between acquired and innate 
immunity [17], therefore play pivotal roles in protection 
against virus infection and in anti-tumor immunity [18, 
19].
The aim of this review is to present a framework for 
the role of γδ T cells in modulating immune responses 
against various pathogens, particularly influenza virus, 
and also to describe their applicability to develop novel 
therapeutic approaches for viral infections as well as their 
restrictions.
Main text
Overview of immune response to influenza infection
Innate cells like neutrophils and macrophages are the 
first leukocytes infiltrated to the lung upon influenza 
virus infection and secrete different cytokines, in par-
ticular, pro-inflammatory cytokines, causing recruitment 
of other leukocytes to the infection site [20]. In addition, 
neutrophil has been shown to present viral antigen on 
its surface, leading to activation and direction of  CD8+ 
T cells into the influenza infected-lung [21]. Moreover, 
activated macrophage is able to release several inflamma-
tory cytokines that are capable of influenza virus inhibi-
tion [22].
Following influenza infection, natural killer cells are 
recruited into the respiratory tract, mainly through 
blood, in response to the expression of their chemokine 
receptors including CCR2, CCR5, and CXCR3 [23–25]. 
NK cells activation contributes to destruction of influ-
enza-infected cells via secretion of perforins, granzyme 
B, and IFN-γ [26, 27]. Furthermore, in the early stages of 
influenza virus infection, innate lymphoid cells includ-
ing cytotoxic NK cells and other innate lymphoid cells 
(ILCs), innate counterparts of T cells, have been shown 
to be effective. In particular, ILC1 induces the cytolysis 
of influenza-infected cells and ILC2 is trafficked into lung 
upon influenza infection and becomes activated, releas-
ing amphiregulin (Areg), which contributes to repairing 
the damaged tissue [28, 29].
Another pivotal member of innate cells is dendritic 
cell (DC), a professional antigen-presenting cell (APC), 
bridging innate and adaptive compartments of immune 
systems. DCs are generally classified into 2 categories: 
 CD11c+ conventional DCs (cDCs), and  CD11c− plas-
macytoid DCs (pDCs) [30, 31]. Compared to these sub-
types of DCs, there are  CD103+ cDCs with the ability to 
uptake viral antigen and migrate to draining lymph nodes 
(DLNs) and are known to be the most efficient cross-pre-
senters of the immune system [32, 33]. And these cDCs 
have been shown to process and present influenza A 
virus (IAV) antigens to  CD8+ T cells. Furthermore, both 
conventional and plasmacytoid DCs act as anti-influenza 
agents [34].
Recently, more studies have focused on other members 
of innate immunity including mucosal-associated invari-
ant T (MAIT), natural killer T (NKT), and γδ T cells that 
respond to the influenza virus.
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MAIT cells are evolutionarily-conserved, innate-like 
lymphocytes constituting 5% of the total T cell pool in 
humans. MAIT cells express a semi-invariant αβ T cell 
receptor (TCR), which has been demonstrated to identify 
bacterial-derived vitamin B2 derivatives presented by the 
MHC class I-related gene protein (MR1) [35, 36]. Moreo-
ver, it has been indicated that MAIT cells contribute to 
protection against several intracellular bacteria [37, 38]. 
Accumulating evidence substantiates that a loss and/or 
efflux of MAIT cells from the blood to the site of infec-
tion are observed in patients infected with the influenza 
virus [39, 40]. These studies manifest that a decrease in 
the number of MAIT cells during acute influenza infec-
tion could impair protective anti-bacterial immunity, 
leading to the elevation of bacterial co-infection risk that 
ultimately would result in higher morbidity and mortality 
[41].
Another innate T cell subset is the natural killer T 
that is restricted by the glycolipid α-galactosylceramide 
(αGC) presented on MHC class I-like CD1d molecules. 
In addition to expressing αβ-TCRs, this subset expresses 
NK cell markers including CD3, CD56 (humans) or 
NK1.1 (mice), and is broadly classified into 2 groups: type 
I invariant NKT (iNKT) cells expressing the invariant 
Vα14-Jα18 TCRα chain paired with either Vβ2, Vβ7, or 
Vβ8 in mice and Vα24-Jα18/Vβ11 in humans, and type 
II diverse NKT cells, displaying very diverse αβ-TCR 
gene pairings [42, 43]. An array of animal studies demon-
strated that activation of iNKT cells leads to a reduction 
of body weight loss and viral lung titers [44, 45]. Simi-
larly, one study showed that the αGC usage as a vaccine 
adjuvant improved the long-term survival of  CD8+ cyto-
toxic T lymphocytes, providing heterologous protection 
in a mouse model of influenza infection [46]. Intriguingly, 
one pre-clinical study demonstrated that vaccination 
with inactivated influenza A/PR/8/34 virus adjuvanted 
with αGC in BALB/c mice elicited IgG and IgA antibod-
ies, which lasted for months and further boosted cellular 
immunity in comparison to mice immunized just with 
inactivated PR8 virus [47]. Taking together, this subset 
of innate T cell is considered as an innate and adaptive 
immune response modulator based on its role in estab-
lishing optimal influenza-specific T and B cell responses 
in the mucosal and systemic compartments. Another 
important participant in the immune response against 
influenza infection is the γδ T cell, which we will talk 
about later.
On the other hand, there is an adaptive immune 
response that differs from innate immunity. The adaptive 
immune system-belonging cells present various receptors 
with precise specificity for antigens derived from particu-
lar pathogens. This adaptive immunity constitutes the 
second line of barrier against influenza virus infection. 
The adaptive-attributed humoral and cellular immune 
responses are mediated by virus-specific antibodies and 
T cells, respectively [48]. Following influenza infection, 
virus-specific antibodies are elicited and those specific 
for surface glycoproteins, hemagglutinin (HA) and neu-
raminidase (NA), are directed to these antigens, resulting 
in virus neutralization and spread limitation, respec-
tively [49, 50]. Of note, this antibody-mediated immune 
response is predominantly strain-specific [51].
Activation of different immune cells upon influenza 
infection further induces cellular immunity consisting 
of  CD4+ T cells,  CD8+ T cells, and regulatory T cells 
(Tregs). Following recognition of virus-derived MHC 
class II-associated peptides on APCs by  CD4+ T cell, 
this T cell becomes activated and forms either T-helper 
1 (Th1) or T-helper 2 (Th2) type T cells [51]. Th2 cells 
produce IL-4 and IL-13, leading to the promotion of B 
cell responses [52], whereas, Th1 cells produce IFN-γ and 
IL-2 that mainly contribute to cellular immune responses 
[53]. In addition, virus-specific  CD8+ T cells, as men-
tioned before, are recruited at the site of infection and are 
able to recognize and eliminate influenza virus-infected 
cells and therefore prevent production of progeny virus 
[48].
Principles of γδ T cells
T lymphocytes are classified structurally into two sub-
groups based on different glycoprotein chains of T cell 
receptors known as αβ and γδ, each of which are com-
posed of a variable (V), constant (C), and joining (J) seg-
ment generated through VDJ recombination [54, 55]. 
The γδ-TCR loci gene rearrangement occurs at an early 
stage in the fetal thymus and prior to αβ-TCR genes rear-
rangement [56], therefore, intraepithelial lymphocytes 
(IELs) with γδ-TCR (γδ IELs) are believed to be the initial 
type of T cells localizing in the epithelium and so play an 
important role in the immune responses during the peri-
natal period, prior to TCR αβ T cell activation [57].
Among two major subgroups of γδ T cells, defined by 
the usage of either Vδ1 or Vδ2 TCR, Vδ1 subset, paired 
with different Vγ chains (comprising Vγ2/3/4/5/8), con-
stitutes the less frequent population and is mainly found 
in epithelial tissues and mucosae and involves in the first 
barrier defense against infections, whereas Vδ2 subset, 
which is uniquely associated with Vγ9 chain (called Vγ9 
Vδ2), is more abundant in peripheral blood and plays 
roles in defense against intracellular and circulating path-
ogens [58, 59]. By contrast, γδ T cells expressing Vδ3 with 
either Vγ2 or Vγ3 (termed Vδ3 subset) are the smallest 
subset of γδ T cells predominantly resident in the liver 
and take participate in the process of chronic viral infec-
tions. Furthermore, the functionality categories of γδ T 
cells, e.g., IL-17-producing γδ T cells or IFN-γ-producing 
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γδ T cells have been described [59]. There has been accu-
mulating evidence demonstrating γδ T cells are involved 
in various aspects of the host immune responses ranging 
from acute and chronic inflammation to killing virus-
infected cells, cancerous cells, and stressed cells [60, 61].
It has also been confirmed that both naturally IFN-
γ- or IL-17-producing γδ T cell subsets express differ-
ent NK cell receptors [including NK group 2 member 
D (NKG2D) receptors and killer immunoglobulin-like 
receptors (KIRs)] that are responsible for controlling the 
γδ T cell-mediated immune responses [62]. On the other 
hand, in order to terminate γδ T cell responses, several 
inhibitory receptors can exert negative signals, specifi-
cally programmed cell death-1 (PD-1) and B and T lym-
phocyte attenuator (BTLA) [62].
γδ T cell‑mediated innate and adaptive immune responses
γδ T cells are regarded to be innate-like lymphocytes 
with crucial role in immune responses or immune regu-
lations by detecting antigens directly in a MHC-unre-
stricted priming manner, resulting in response to stress 
conditions rapidly without the need for clonal selec-
tion and differentiation [15]. In the initiation phase of 
immune responses, γδ T cells may connect innate and 
adaptive immunities, thereby playing crucial roles in anti-
infection, autoimmunity, and antitumor effects [18, 19]. 
Moreover, they produce a large number of inflammatory 
molecules, such as granulocyte–macrophage colony-
stimulating factor (GM-CSF), IFN-γ, and tumor necrosis 
factor (TNF) [63] and also can stimulate other immune 
cells including monocytes, neutrophils, dendritic cells, 
B lymphocytes, and different subtypes of T cells [64]. 
In this context, in humans, γδ T cells induce B cell class 
switching by expressing several factors including: (1) IL-4 
and IL-10 cytokines, involved in immunoglobulin class 
switching; (2) CXCR5, a chemokine receptor localizing B 
cells in follicles; (3) CD40 ligand (CD40L), promoting B 
cell activation; (4) IL-21 and IFN-γ cytokines, which are 
crucial for the development of follicular helper T cells 
and germinal center-resident B cells, suggesting a direct 
role for γδ T cells in modulating humoral immunity by 
helping B lymphocytes to produce different classes of 
antibodies [65–67].
In comparison to αβ T cells, γδ T cells not only par-
ticipate more extensively in innate immunity and homeo-
static processes [68], but also actively produce IL-17 and 
IFN-γ in response to antigenic stimulation in tissues [69]. 
Several studies have shown that IL-17 demonstrates both 
protective and pathogenic features in the immune system 
and the involvement of this cytokine is of importance 
in host defense against various infectious organisms 
[70–72]. These non-conventional T cells can also pro-
mote adaptive-like responses by sharing functions with 
APCs, pro-inflammatory and cytotoxic effector cells, 
and immune-regulatory cells [73]. Consequently, before 
effective expansion and activation of antigen-specific αβ 
T cells, γδ T cells represent the first line of immune bar-
rier to prevent infection from pathogens [74].
γδ T cells role in antiviral immunity
Despite the role of NK cells and  CD8+ αβ T cells in the 
early and the late phase of controlling viral infections 
(respectively), some studies have addressed the impera-
tive role of T lymphocytes expressing the γδ T cell recep-
tor in reducing viral loads by direct lysis of virus-infected 
cells and by non-cytolytic mechanisms, particularly γδ T 
cell-induced bystander activation of other immune cells, 
as summarized in Table 1.
It seems that γδ TCR-bearing T cells can exert their 
protective role in the killing of virus-infected cells 
directly through the perforin/granzyme cytotoxic path-
way, the apoptosis pathways triggered by death induc-
ible receptors like FAS and tumor necrosis factor-related 
apoptosis-inducing ligand receptors (TRAIL), the natural 
killer group 2, members C and D (NKG2C, D)-mediated 
γδ T cell recognition and destruction, and antibody-
dependent cell-mediated cytotoxicity (ADCC) [9, 10, 
75–78]. In West Nile virus (WNV) infected mice, a trend 
toward significantly lower perforin expression level was 
noted in TCRδ−/− mice in comparison with wild type 
or TCRβ−/− mice, suggesting the ability of γδ T cells to 
directly produce perforin or their potential to modulate 
the production of perforin by αβ T cells [75]. In human 
immunodeficiency virus (HIV)-positive patients, per-
forin-mediated HIV-infected  CD4+ T cells destruction 
by Vδ1+ γδ T cells has also been reported [76]. Regard-
ing Epstein–Barr virus (EBV)-infection, NKG2D receptor 
triggering and the cytotoxic pathways of TRAIL and Fas/
Fas ligand (FasL) were outlined as the major mechanisms 
involved in clearing EBV-transformed autologous lymph-
oblastoid B cell lines by Vγ9Vδ2 T lymphocytes [79]. It 
has also been revealed that an up-regulation of NKG2D 
ligand expression on the surface of target cells induced 
by Zika virus (ZIKV) infection makes them more sus-
ceptible to lyse by  NKG2D+ Vδ2+ T cells through per-
forin pathway [80]. Although NKG2D is originally known 
as an activating receptor for NK cells, it also acts as a 
potent co-stimulatory receptor of human Vγ9Vδ2 T 
cells. Furthermore, NKG2D-mediated cytotoxic func-
tion of Vγ9Vδ2 T cells by triggering the release of cyto-
lytic granules through receptor-ligand recognition has 
been discussed recently [81]. Alternatively, NKG2C (an 
activating NK cell receptor of the C-type lectin)-medi-
ated cytotoxicity was reported to be involved in the lysis 
of HIV-infected  CD4+ T cells by NKG2C-bearing Vδ1+ 
γδ T cells [77]. Of importance, the potential role of Fcγ 
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receptor III (CD16)-bearing Vδ2 T cells in the control 
of HIV type 1 disease through ADCC in the presence of 
specific antibodies that target antigens expressed on the 
surface of infected cells has been proposed [78].
The mechanisms underlying γδ T cell-mediated 
non-cytolytic antiviral activity consist of the produc-
tion of cytokines (notably IFN-γ) and β chemokines like 
macrophage inflammatory protein (MIP)-1α, MIP-1β, 
and RANTES (regulation on activation, normal T cell 
expressed and secreted) [82, 83]. Upon infection with 
viruses like WNV, vaccinia virus (VV), hepatitis C virus 
(HCV), murine cytomegalovirus (MCMV), it has been 
reported that an early immune response (as a first line of 
host defense) involving IFN-γ-secreting γδ T cells is criti-
cal to control viral infection [75, 83–86]. IFN-γ presents 
potent antiviral activity by interfering with the viral rep-
lication through the induction of intracellular signaling 
pathways following interferon binding to its cell-surface 
receptors and subsequent up-regulation of a set of IFN-
stimulated genes (ISGs) products that directly inhibit key 
steps of the replicative life cycle of viruses and by induc-
ing the death of target cells through the modulation of 
both innate and adaptive immune responses [86–88]. 
However, little is known about the mechanism by which 
IFN-γ-secreting γδ T cells regulate the replication of dif-
ferent viruses.
After primary herpes simplex virus type 1 (HSV-1) 
infection in mice, it has been observed that viral repli-
cation is suppressed by IFN-γ-producing γδ T cells and 
macrophages that infiltrate into the infected trigemi-
nal ganglion (TG). Cross-regulation between these two 
types of immune cells is required for their accumula-
tion and antiviral functions in the TG. In this manner, 
synergistic effects of γδ T cell-produced IFN-γ with 
macrophage-derived TNF-α and nitric oxide (NO)-
producing enzymes, i.e., inducible nitric oxide synthase 
(iNOs) can dramatically restrict viral replication [84, 89]. 
On the other hand, the possible contribution of IFN-γ-
producing gamma-delta T cells to induce the neutraliz-
ing IgG responses independently of αβ T cell help in αβ 
T cell-deficient mice infected with either live vesicular 
stomatitis virus (VSV) or a recombinant vaccinia virus 
expressing the VSV glycoprotein has been described 
[82]. Of note, CD16 was also reported to be a TCR-inde-
pendent activating receptor on human cytomegalovirus 
(HCMV)-induced Vdelta2-negative gamma-delta T cells, 
able to promote antiviral activity against IgG-opsonized 
HCMV-infected fibroblast cells by antibody-mediated 
CD16-induced IFN-γ secretion, called antibody-depend-
ent cellular inhibition (ADCI) [90].
On the other hand, the production of antiviral fac-
tors MIP-1α, MIP-1β, and RANTES by Vγ9Vδ2-
bearing lymphocytes has been shown to block HIV 
replication in  vitro by inhibiting the CCR5 co-receptor 
that is required for HIV entry [91]. Alternatively, the 
involvement of NKp30, an activating receptor for NK 
cells, expressed on activated V delta 1  T cells in induc-
ing β chemokines production, followed by the inhibi-
tion of CCR5-tropic HIV-1 strains replication has been 
described [92]. Taken together, unlike αβ T cells, γδ T 
cells, which possess innate and adaptive immune char-
acteristics, play a crucial part in the front line of defense 
against various viral infections.
Respiratory γδ T cells
Unlike αβ T cells, the preferential tropism of γδ T cells 
for non-lymphoid sites such as the skin, respiratory, 
digestive, and reproductive tracts may be related to their 
potential role in providing the early protection against 
invading pathogens and/or in mitigating the tissue-dam-
aging side effects of immune responses in an immune 
regulatory manner [100, 101]. In this context, there is 
increasing evidence to reveal the role of γδ TCR-bearing 
T lymphocytes in maintaining and protecting normal 
functions of the airway, which has been reviewed in Ref. 
100.
Heterogeneous populations of γδ T cells (predomi-
nantly Vγ1+ and Vγ4+) with distinct functions (mostly 
immunoregulatory role) are found in the lung [101, 102] 
and responses of lung-specific γδ T cells have also been 
reported in a variety of lung diseases including bacterial, 
viral, and fungal infections, allergic disease, inflamma-
tion and fibrosis, and cancer (reviewed in Ref. 101). For 
instance, during acute respiratory syncytial virus (RSV) 
infection, the beneficial role of activated γδ T cells as the 
main source of IL-17A in regulating viral responses and 
reducing lung inflammation in RSV-infected adult mice 
has been reported. Compared with adult mice, a signifi-
cant decrease in γδ T cell-mediated IL-17A responses 
was noted in RSV-infected neonatal mice during initial 
infection. On the other hand, increased levels of IL-1β 
and IL-6 (as activated inflammasome markers) involved 
in the induction of IL-17A as a product of inflammas-
ome-activated γδ T cells was also only observed in the 
lungs of RSV-infected adult mice, indicating a defect 
in inflammasome activation upon neonatal RSV infec-
tion. Interestingly, lung pathogenesis in neonates was 
reduced by exogenous IL-17A administration, while neu-
tralization of IL-17A resulted in increased inflammatory 
responses in adult mice, suggesting the inflammation-
inhibiting effects of IL-17-producing γδ T cells in the 
mouse model of RSV disease [103].
However, the increased recruitment of Vγ4+ γδ T 
cells to the lung and subsequent production of IFN-γ, 
TNF, RANTES, IL-10, IL-4, and IL-5 in a time-depend-
ent manner (i.e., γδ T cell-mediated early production of 
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Th1, followed by a late surge of regulatory/Th2 cytokines 
release) were observed after RSV challenge in BALB/c 
mice immunized with a live vaccine vector expressing 
RSV F protein. During the secondary challenge, In  vivo 
depletion of γδ T cells did not affect viral clearance but 
resulted in reduced lung inflammation and slightly 
increased peak viral replication in vaccinated mice [104]. 
Such differences as cytokine profile and/or γδ T cell-
mediated disease pathology (e.g. alleviating or inducing 
lung inflammation) seems to be related to the presence 
of distinct populations of γδ+ T cells in the lung with spe-
cific roles [100].
γδ T cell effects in defense against influenza infection
Recently, it has been observed that γδ T cells (mostly 
GV9-TCRγ-expressing γ9δ2) are able to destruct influ-
enza A virus-infected cells as efficient as  CD8+ T cells 
or NK cells in a polycytotoxic manner and by releas-
ing IFN-γ against infected cells in  vitro [61]. Investiga-
tion on pigs, as human-like IAV infection models, has 
substantiated the role of γδ T cells as early defending 
modules of the innate-like, adaptive immune system in 
anti-H1N1pdm09 infection activities. Significant aug-
mentation of γδ T cells-induced perforin secretion in 
IAV-infected pigs’ nasal mucosa along with enhancement 
of γδ T cells-producing CD8 in respiratory system lymph 
nodes constitute ample evidence to indicate the effective-
ness of γδ T cells in controlling IAV infection [105].
IL-17A-producing γδ T cells were shown to be involved 
in initiating protective immunity and mediating lung 
homeostasis and repair in a neonatal mouse model of 
influenza virus. During neonatal influenza (H3N2) virus 
infection, lung accumulation of IL-17A-producing γδ T 
cells, associated with the increase in lung epithelial cell-
derived IL-33, resulted in IL-17A-dependent IL-33-medi-
ated promotion of local type II immunity and infiltration 
of group 2 innate lymphoid cells and regulatory T cells to 
the lung, which thereby led to the augmented amphiregu-
lin secretion and tissue repair [14]. A very recent study 
has revealed that immediately upon infection with influ-
enza virus, Vγ4+ γδ T cells, infiltrated by means of 
CXCR3 receptor, undertake the task of providing early 
defense barrier against infection. This mission is fol-
lowed by induction of IL-17A production, aimed at acti-
vation of protective neutrophils and NK cells in tracheal 
mucosa and so suppressing invasive viral replication after 
influenza infection [106]. Similarly, co-culturing H3N2-
infected human nasal epithelium with PBMC showed 
that IAV infection stimulates both NK cells and γδ T cells 
(especially Vδ2 γδ T cells) against infected targets in vitro 
[107]. In myxovirus protein 1 (Mx1)-congenic C57BL/6 
mice models, those consuming a low-carbohydrate, high 
fat ketogenic diet (KD) showed lower viral titers and 
improved survival in response to lethal IAV infection due 
to IL-17-producing γδ T cell-mediated killing of IAV-
infected airway epithelial cells, expanded in response to 
KD in the lung, and KD-expanded γδ T cell-mediated 
improved lung barrier integrity [108].
In a mouse model of influenza (H3N2) virus infec-
tion, it was observed that in the lung of infected mice, 
the percentage of V gamma  4+ γδ T cells was gradually 
augmented post-infection, peaked at day 10, which was 
paralleled by an increase in the number of inflamma-
tory macrophages expressing heat-shock protein (HSP) 
mRNA. However, V gamma  2+/V gamma  1+ γδ T cells 
were the dominant γδ T cell phenotype on day 13 after 
infection, indicating the possible role of some of these 
lymphocytes in responding to  HSP+ cells and resolving 
inflammatory process upon influenza infection [13]. It 
was also found that an increased frequency of IL-22-pro-
ducing retinoic acid receptor-related orphan receptor-γt 
(RORγt)-positive αβ and γδ T cells, and innate lymphoid 
cells in the initial phase of influenza A (H3N2) virus 
infection was associated with the limited lung inflamma-
tion and so a more controlled secondary bacterial infec-
tion. Of note, during lethal and sublethal viral infection, 
high levels of IL-22 had no effect on the control of virus 
propagation and the development of virus-specific  CD8+ 
T cell response [109]. Moreover, IL-21 has been shown 
to have a key modulatory role in controlling γδ T cells 
propagation in the respiratory tract and its presence is 
necessary for preventing hyperinflammatory responses 
of γδ T cells through overexpression of IL-17 and subse-
quent lung injury [110]. Similarly, depletion of serpinb1a 
in IAV-infected mice models resulted in augmentation of 
IL-17+ γδ T cells and  CD4+ Th17 cells and so increased 
the rate of mortality and impaired immune responses 
among depleted mice, mentioning the anti-inflammatory 
role of serpinb1a in IAV-driven overproduction of γδ T 
cells [111]. Nevertheless, in wild-type mice, the detri-
mental effect of type I IFNs induced during primary non-
lethal influenza infection on increased susceptibility to 
secondary Streptococcus pneumonia infection by negative 
regulation of lung γδ T cell-mediated IL-17 production 
and IL-17-induced neutrophil recruitment, involving in 
lung immunity to bacterial infection, has been reported 
[112]. In the context of postinfluenza occurrence of lethal 
pneumococcal pneumonia, it has been shown that IL-27 
expression in response to IAV infection hinders IL-17-ex-
pressing γδ T cells production by involvement of STAT1 
factor and thereby deprives the host from the immunity 
related to IL-17 expression by γδ T cells after initial influ-
enza infection [113].
The non-specific protective role of trehalose 6,6′-dimy-
colate (TDM) against influenza virus infection by induc-
ing lung accumulation of γδ T cells following intravenous 
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exposure in mice has been described. Depletion of γδ T 
cells in vivo impaired the resistance of TDM-treated mice 
to lethal influenza A (H3N2 and H1N1) virus infection, as 
did depletion of either αβ T cells or NK cells, indicating 
a complementary role for γδ T cells, αβ T cells and NK 
cells in protecting mice against influenza virus infection. 
On the other hand, γδ T cells from TDM-treated mice 
exhibited a significant role in the host defense against 
influenza virus infection by recognizing an unprocessed 
whole HA molecule of either H1 or H3 subtype in a 
major histocompatibility complex-independent manner 
[114].
Highly pathogenic avian influenza (HPAI) H5N1 
viruses have recently been reported to activate γδ T cells 
as the first line of the host immune defense via the trim-
mers of viral HA proteins, leading to the up-regulation 
of CD69 as an early activation marker on γδ T cells. This 
activation depends on both sialic acid receptors on the 
surface of γδ T cells and the glycosylation of HA proteins. 
In this manner, the protective activity of HA-induced γδ 
T cells against HPAI H5N1 virus infection is mediated 
directly through IFN-γ production or indirectly through 
the regulation of other immune cells by secretion of 
immunomodulatory cytokines. Moreover, H5N1 infected 
TCRδ−/− mice showed an increased mortality rate and 
more severe lung injury, revealing the important part 
played by γδ T cells in the infection control. On the other 
hand, the rapid response of γδ T cells to viral infection, 
as well as the resistance of γδ T cells to HPAI H5N1in-
fection increase the ability of these lymphocytes to con-
trol viral infection over other immune cells [60]. On the 
contrary, after Vγ4+ γδ T cell subset depletion, the sur-
vival rate of mice infected with the influenza A (H1N1) 
pdm09 virus was improved by reducing Vγ4+ γδ T cell-
mediated IL-17 secretion, lung immunopathology injury, 
and inflammatory cell infiltration [115]. These contra-
dictory results are likely due to the presence of different 
γδ T cell subsets in the lung with distinct functions and/
or due to the use of different influenza virus strains and 
treatment methods [60, 100]. In this context, it has also 
been demonstrated that  CD56+ subset of Vγ9Vδ2 T cells 
show higher degree of cytotoxicity against IAV infection 
when compared to  CD56− equivalent, which is due to the 
specific CD16-mediated degranulation concomitant with 
 CD56+ Vγ9Vδ2 T cells activity [116].
Using a model of A549 cells, human lung alveolar epi-
thelial cells, infected by human (H1N1) influenza virus, 
it was found that aminobisphosphonate pamidronate 
(PAM)-expanded Vγ9Vδ2 T cells from PBMC of healthy 
donors were efficiently able to control influenza patho-
genesis by non-cytolytic inhibition of influenza repli-
cation and by direct killing of influenza-infected cells 
through cytolytic pathways of perforin/granzyme B, 
TRAIL, and Fas-FasL in a NKG2D-mediated cell to cell 
contact-dependent manner [9]. Regarding the ability of 
the influenza virus to replicate in human macrophage, 
human Vγ9Vδ2 T cells that are activated by IPP in vitro 
have also been demonstrated to have potent cell-killing 
activity in human (H1N1) and avian (H9N2 or H5N1) 
influenza virus-infected human monocyte-derived mac-
rophages (MDMs) as the model, suggesting the het-
erotypic nature of Vγ9Vδ2 T lymphocyte responses to 
influenza A subtypes. The cytotoxic activity of activated-
Vγ9Vδ2 T cells requires NKG2D recognition and is 
mediated by both Fas-FasL and perforin/granzyme B 
pathways [10]. Furthermore, in an IAV-infected MDMs 
model, virus-activated Vγ9Vδ2 T cells driven from PBMs 
of healthy donors were shown to preferentially express 
the chemokine receptors CCR1, CCR5, and CXCR5, 
among which the CCR5 is associated with the regula-
tion of Vγ9Vδ2 T cell trafficking to virus-infected cells by 
binding to its ligands (CCL3, CCL4, and CCL5) produced 
in response to influenza infection. Of note, compared 
to human (H1N1) influenza virus, considerably higher 
Vγ9Vδ2 T cell-mediated expression of CCR5 chemokine 
ligands is stimulated by avian (H5N1 and H9N2) influ-
enza viruses, which may be due to higher severity of 
infections among avians [11].
In young children, the role of γδ TCR + IFN-γ+ T cells 
induced by trivalent live-attenuated influenza vaccine 
(LAIV) in providing further protective effects against 
influenza infections, compared with trivalent inacti-
vated influenza vaccine (TIV), has been proposed [117]. 
After influenza vaccination, in young recipients, virus-
activated γδ T cells were significantly higher than those 
in elderly group, indicating the possible negative effects 
of age-induced changes of γδ T cells responses on vac-
cine efficacy [118]. Interestingly, the frequency of T cells 
carrying γδ TCR in non-smokers was significantly higher 
than smokers following LAIV vaccination, indicating 
inhibitory effects of smoking in LAIV-induced altera-
tions in the percentage of γδ T cells [119]. Concerning 
the harsh reaction of smokers suffering lung disease to 
respiratory infections, an intriguing study explored the 
effect of cigarette smoke on recovery from IAV infection 
among mice models and revealed that smoke-enhanced 
IL-17 production in the lung of mice exposed to cigarette 
smoke hampers the efficient activation of γδ T cells and 
so significantly decreases the possibility of survival after 
infection [120]. Additionally, it has been reported that 
obesity is correlated with the low numbers of γδ T cells in 
the peripheral blood, as well as reduced homeostasis and 
antiviral functions of γδ T cells, leading to increase the 
susceptibility of obese patients to respiratory infections 
(notably influenza virus) and subsequently higher rate of 
mortality among them. Also, remnant γδ T cells in obese 
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individuals majorly lack the IL-2Rα and so are unable to 
be primed efficiently [121].
Regarding the possible correlation between variants of 
chromosome Y and incidence of IAV infection in males, 
it indicated that a number of particular ChrY consomic 
mice, like  ChrYPWD mice, are more susceptible to IAV 
infection. Further analysis attributed this phenomenon 
to higher levels of some IL-17-expressing subsets of γδ 
T cells (Vγ4+ and Vγ1−Vγ4−) in  ChrYPWD mice group 
without any observed alteration in level of IFN-γ among 
them, which together increase the fatality rate [122]. Col-
lectively, these studies highlight a crucial role for γδ T 
cells in conferring protection and recovery from influ-
enza virus infections. γδ T cell-mediated antiviral activi-
ties to eliminate influenza-virus-infected respiratory cells 
are shown in Figs.  1 and 2. Also, an overview of IAV-
induced γδ T cell responses is summarized in Table 2.
γδ T cell‑based emerging therapeutic approaches
There is increasing interest to find alternative strategies 
aimed to offer a safe and accessible option for treating 
viral infections. In this context, stimulatory targeting of 
γδ T cells to activate and allow them to show their effec-
tor functions quickly, regardless of virus subtypes and the 
emergence of drug-resistance viral strains, can be con-
sidered as a promising strategy. For instance, in human-
ized mice, exogenous administration of PAM, a common 
treatment for osteoporosis and Paget’s disease, has been 
shown to decrease the disease severity and the number 
of death caused by H1N1 and H5N1 influenza viruses 
Fig. 1 Schematic representation of effector mechanisms of γδ T cells in response to influenza virus infection of respiratory epithelium. Upon 
infection with influenza virus, infected cells secrete CCL3, CCL4, and CCL5 chemokines and thereby recruit γδ T cells, harnessing chemokine-binding 
CCR5 receptor, to the site of infection. Activated effector γδ T cells release cytokines and chemokines such as IFN-γ, IL-17, IL-22, as well as cytolytic 
proteins including perforin and granzyme B, which can directly lyse the infected cells and can also recruit other immune cells such as natural killer 
(NK) cells and neutrophils to aid killing or healing infected cells. Moreover, γδ T cells expressing IL-17A, binds to IL-17A receptor on lung epithelial 
cells, producing IL-33 and thereafter drive colonic group 2 innate lymphoid cell (ILC2) activation during influenza virus infection. The activated ILC2 
produces Amphiregulin (Areg), which participates in pulmonary tissue repair upon influenza infection. In addition, IL-22, released from both γδ T 
cells and activated NK cells, is effective in preserving the homeostasis of mucosal barrier of influenza-infected respiratory tract and also plays a key 
regulatory role in microbial host defense after influenza infection
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by enhancing human Vγ9Vδ2 T cell immunity indirectly 
through the induction of intracellular accumulation of 
IPP, a metabolite in the mevalonate pathway that selec-
tively expands human Vγ9Vδ2 T cells, suggesting the 
potential application of PAM in human clinical trials 
[123]. The potential applicability of PAM-induced activa-
tion of human Vγ9Vδ2 T cells to control EBV-induced 
lymphoproliferative disease has also been reported [79]. 
Using a co-culture system containing Huh7 hepatoma 
cells carrying the subgenomic HCV replicon (Rep60 
cells) and PBMC of healthy and  HCV+ donors, it was also 
found that treatment with drugs containing non-pep-
tidic antigens [zoledronic acid (ZOL) and bromohydrin 
pyrophosphate (BrHPP)] could influence HCV replica-
tion by expanding IFN-γ-producing Vγ9Vδ2 T cell pop-
ulation, suggesting the feasibility of using non-peptidic 
drugs as an innovative therapeutic approach in patients 
suffering from HCV [86].
On the other hand, Vδ2+ γδ T cells from HIV-infected 
individuals were demonstrated to respond strongly 
to ZOL plus IL-2, leading to rapid expansion of CD16-
expressing Vδ2+ subset associated with enhanced 
ADCC-dependent CD16-mediated antiviral activ-
ity of Vδ2+ γδ T cells, suggesting the capacity of ZOL/
IL-2-expanded Vδ2+ γδ T cell-based immunotherapy 
in HIV patients [124]. Modulation of  CD16+ Vδ2neg γδ 
Fig. 2 Cartoon overview of γδ T cells receptor-dependent interaction with influenza virus or influenza-virus-infected respiratory cells. a Activation 
of γδ T cells by the interaction between NKG2D (natural killer group 2D) receptor of γδ T cells with its ligands, MHC class I chain-related sequence A 
and B (MICA and MICB), expressed on the surface of influenza-infected epithelial cells, inducing the release of some cytokines and cytolytic proteins, 
somehow halting the influenza infection. b The interaction of influenza haemagglutinin (HA) on the surface of influenza viruses with sialic acid 
receptors plays a key role in the activation of γδ T cells, triggering the production of interferon-γ (IFN-γ). c γδ T cells utilize TNF-related apoptosis 
inducing ligand (TRAIL) for killing of influenza-infected cells. Infected epithelial cells express death receptors TRAIL-R1 or TRAIL-R2, identifying their 
ligand (Apo2 ligand) on the surface of influenza infection-activated γδ T cells and undergo apoptosis through Caspase-dependent pathways. d) 
FAS ligand expressed by γδ T cells, when exposed to FAS receptor available on influenza-infected cells surface activates the pathway of FAS-FASL 
apoptosis to destroy the infected cell
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T cell-mediated ADCI by exogenous administration of 
HCMV-specific IgGs may also provide a promising anti-
human CMV strategy [90]. ZOL-mediated human Vδ2 
cell targeting that are involved in the control of WNV 
infection in  vitro by both cytotoxic and non-cytotoxic 
mechanisms may facilitate a novel immunotherapy strat-
egy to the treatment of WNV infection [125].
Of note, adoptive immunotherapy using HIV-1-reac-
tive CD4-negative γδ T cells, able to mediate antiviral 
activity, may be playing a critical role in the control of 
HIV-1 infection. However, the advancement of γδ T cell-
based adoptive cellular immunotherapy for HIV-1 infec-
tion has been constrained by the inability to isolate or 
expand sufficient numbers of viable γδ T cells [126].
Concerning the construction of a universal vaccine 
against distinct subtypes of influenza A virus, Jameson 
et al. showed that human PBMC-derived Vγ9Vδ2 T cells 
induce CD25 and CD69 expression and also produce 
Table 2 Anti-influenza mechanisms of γδ T cells in the respiratory tract
IAV, influenza A virus; THP-1 cells, a human monocyte cell line; NK cells, natural killer cells; MX1, myxovirus protein 1; KD, ketogenic diet; HSP, heat shock protein; A549 
cells, human lung alveolar epithelial cells; HA, hemagglutinin; LAIV, live-attenuated influenza vaccine
Study Host γδ subsets Anti‑influenza mechanism
Sant et al. [61] Human γδ T cells along with target IAV-infected THP-1 
cells
Vγ9Vδ2 Vγ9Vδ2 T cell-mediated IFN-γ-dependent anti-influenza 
activity
Killing of target cells by Vγ9Vδ2 T cells with an equivalent 
efficiency to  CD8+ T cells and NK cells
Schwaiger et al. [105] Pigs, as human-like IAV infection models pan γδ Anti-IAV activity mediated by γδ T cells in a perforin-
dependent cytotoxic pathway
An increase in the percentage of CD8 expressing γδ T 
cells in route of viral entry
Xi-zhi et al. [14] A neonatal mouse model pan γδ IL-17A-producing γδ T cell-mediated increased lung 
epithelial cell-derived IL-33
IL-33-mediated lung repair through the infiltration of 
group 2 innate lymphoid cells and regulatory T cells to 
the lung
Palomino et al. [106] C57BL/6 mice pan γδ Recruitment of γδ T cells to the site of infection in a 
CXCR3 receptor-dependent fashion
IL-17A-producing γδ T cell-mediated enhanced protec-
tive cells (neutrophils and NK cells) recruitment to the 
tracheal mucosa
Goldberg et al. [108] Mx1-congenic C57BL/6 mice models pan γδ KD-expanded γδ T cell-mediated improved lung barrier 
integrity
Viral clearance during lethal influenza infection in airway 
epithelium by γδ T cells expressing IL-17
Carding et al. [13] C57B1/6 J mice Vγ4+
Vγ2+/Vγ1+
A possible role of γδ T cells in responding to  HSP+ cells 
and resolving inflammatory process upon influenza 
infection
Ivanov et al. [109] IL-22−/− and wild type mice pan γδ IL-22-producing γδ T cell- dependent limited lung 
inflammation and increased immunity to bacterial 
infection at early phase of IAV infection
Li et al. [9] Human γδ T cells along with IAV-infected A549 cells Vγ9Vδ2 NKG2D-induced Vγ9Vδ2 T cell-mediated cytotoxicity in 
perforin/granzyme B, TRAIL, and Fas-FasL dependent 
pathways
Qin et al. [11] Human PBMC infected with IAV pan γδ CCR5-mediated regulation of Vγ9Vδ2 T cell trafficking to 
virus-infected site by binding to its ligands secreted 
from infected cells upon IAV infections
Dong et al. [60] TCR-δ−/− and wild type mice pan γδ Unprocessed whole HA molecule-restricted activation 
of γδ T cells
IFN-γ-mediated antiviral immunity against IAV infection 
provided by HA-induced γδ T cells
γδ T cell-induced bystander activation of other immune 
cells by secretion of immunomodulatory cytokines
Stervbo et al. [118] Human donors pan γδ Detrimental effects of age and smoking on LAIV-induced 
γδ T cell responsesHorvath et al. [119]
Moser et al. [110] IL-21R KO mice, C57BL/6, and CD45.1 mice pan γδ Modulatory role of IL-21 and serpinb1a in the control of 
negative effects of overstimulation of IL-17-producing 
γδ T cells in the respiratory tract after IAV infection
Zhao et al. [111] Wild type and serpinB1−/− mice
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IFN-γ upon IAV infection, promisingly suggest the abil-
ity of Vγ9Vδ2 T cells in providing effective cross-reactive 
responses to IAV infection. In addition, they found that 
incorporation of mevastatin (hydroxymethylglutaryl-
CoA reductase inhibitor) has a negative effect on γδ T 
cells activation, emphasizing the role of mevalonate path-
way in Vγ9Vδ2 T cells efficiency [12]. Interestingly, it has 
been demonstrated that daily consuming of cranberry 
alleviates the symptoms of influenza due to inducing 
γδ T cells proliferation and so reducing the inflamma-
tory cytokines profiles, an akin phenomenon previously 
observed about aged garlic extracts and L-theanine pre-
sent in tea beverage [127–130].
In view of what has been previously discussed, it seems 
that γδ T cell-based immunotherapy may complement 
the traditional therapeutic regimen currently used for 
treating viral infections, particularly influenza A infec-
tion. Information on the potential applicability of γδ T 
cells to elicit improved therapeutic approaches is also 
increasing. In this manner, the strategy of targeting γδ T 
cell by the commercially available drugs containing non-
peptidic antigens, which are currently used in humans, 
can potentially offer a safe and accessible option for treat-
ing viral infections [123]. Of note, one concern regarding 
the clinical application of phosphoantigen-induced γδ T 
cells is whether these cells can enrich at the site of infec-
tions, such as the lung, upon influenza infection. In this 
context, the data regarding the impact of chemokines 
produced by influenza-infected cells on γδ T cell traf-
ficking to the virus-infected site may accelerate their 
potential for immunotherapy [10]. However, the limita-
tions associated with preparing the adequate number of 
desired γδ T cells have restricted the development of cell-
target immunotherapy aimed to boost γδ T cells to clear 
infectious agent. Therefore, there is a need for developing 
additional strategies to overcome this obstacle [126].
Conclusions
While annual vaccination exerts protection against influ-
enza infection, comprehensive perception of immune 
system schemes, especially those related to the innate 
immune system immediately after infection, when con-
fronting influenza virus may help to develop more 
efficient vaccines or improved anti-infection immuno-
therapies, resulting in a decline in the threat of influenza 
infection to human health. In this context, γδ T cells have 
been observed to be primed and activated upon influ-
enza infection of the respiratory tract and play a mediat-
ing role to join the innate immune responses to adaptive 
ones. However, the efficacy of γδ T cells-induced immu-
nity is dependent on various factors including the pre-
dominant subset of γδ T cells at the infection site, the 
amount of recruited γδ T cells, the host immune system 
status, and even the genetics of infected patients. Here, 
we recapitulated and discussed the latest discoveries in 
γδ T cells’ way of action upon influenza virus infection, 
aiming at showcasing one of the few but highly poten-
tial subsets of innate T cells, which can be considered as 
a tool for developing novel and improved protective or 
therapeutic agents.
Abbreviations
PRRs: Pattern recognition receptors; PAMPs: Pathogen-associated molecular 
patterns; RLRs: Retinoic acid-inducible gene-I-like receptors; NLRs: NOD-like 
receptors; TLR: Toll-like receptor; IFNs: Interferons; NK cells: Natural killer cells; 
γδ T cells: Gamma-delta T cells; IPP: Isopentenyl pyrophosphate; MHC: Major 
histocompatibility complex; ILCs: Innate lymphoid cells; Areg: Amphiregulin; 
DC: Dendritic cell; APC: Antigen-presenting cell; cDCs: Conventional dendritic 
cells; pDCs: Plasmacytoid dendritic cells; DLNs: Draining lymph nodes; IAV: 
Influenza A virus; MAIT cells: Mucosal-associated invariant T cells; NKT cells: 
Natural killer T cells; TCR : T cell receptor; MR1: Major histocompatibility com-
plex, class I-related gene protein; αGC: α-Galactosylceramide; iNKT: Invariant 
natural killer T cells; HA: Hemagglutinin; NA: Neuraminidase; Tregs: Regula-
tory T cells; Th: T-helper; V: Variable; C: Constant; J: Joining; IELs: Intraepithelial 
lymphocytes; NKG2D: NK group 2 member D; KIRs: Killer immunoglobulin-
like receptors; PD-1: Programmed cell death-1; BTLA: B and T lymphocyte 
attenuator; GM-CSF: Granulocyte–macrophage colony-stimulating factor; TNF: 
Tumor necrosis factor; CD40L: CD40 ligand; TRAIL: Tumor necrosis factor-
related apoptosis-inducing ligand receptors; ADCC: Antibody-dependent 
cell-mediated cytotoxicity; HIV: Human immunodeficiency virus; WNV: 
West Nile virus; FasL: Fas ligand; EBV: Epstein–Barr virus; ZIKV: Zika virus; MIP: 
Macrophage inflammatory protein; RANTES: Regulation on activation, normal 
T cell expressed and secreted; VV: Vaccinia virus; HCV: Hepatitis C virus; MCMV: 
Murine cytomegalovirus; ISGs: IFN-stimulated genes; HSV-1: Herpes simplex 
virus type 1; TG: Trigeminal ganglion; NO: Nitric oxide; iNOs: Inducible nitric 
oxide synthase; VSV: Vesicular stomatitis virus; HCMV: Human cytomegalovirus; 
ADCI: Antibody-dependent cellular inhibition; RSV: Respiratory syncytial virus; 
Mx1: Myxovirus protein 1; KD: Ketogenic diet; HSP: Heat-shock protein; RORγt: 
Retinoic acid receptor-related orphan receptor-γt; TDM: Trehalose 6,6′-dimy-
colate; HPAI: Highly pathogenic avian influenza; PAM: Aminobisphosphonate 
pamidronate; MDMs: Monocyte-derived macrophages; LAIV: Live-attenuated 
influenza vaccine; TIV: Trivalent inactivated influenza vaccine; ZOL: Zoledronic 
acid; BrHPP: Bromohydrin pyrophosphate.
Acknowledgements
The authors would like to acknowledgement Pasteur institute of Iran.
Authors’ contributions
AS, AG and SMM collected literature, designed and wrote the manuscript. AZ 
and MK and MM edited prepared manuscript for submission. All authors read 
and approved the final manuscript.
Funding
This study was supported by Pasteur Institute of Iran (Grant No. 1137).
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1 Department of Influenza and Other Respiratory Viruses, Pasteur Institute 
of Iran, P.O. Box 1316943551, Tehran, Iran. 2 The Persian Gulf Tropical Medicine 
Page 15 of 18Sabbaghi et al. Virol J          (2020) 17:174  
Research Center, The Persian Gulf Biomedical Sciences Research Institute, 
Bushehr University of Medical Sciences, Bushehr, Iran. 3 Department of Virol-
ogy, School of Public Health, Tehran University of Medical Sciences, Tehran, 
Iran. 
Received: 1 July 2020   Accepted: 5 November 2020
References
 1. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, 
et al. Mortality associated with influenza and respiratory syncytial virus 
in the United States. JAMA. 2003;289(2):179–86.
 2. Rossman JS, Lamb RA. Influenza virus assembly and budding. Virol. 
2011;411(2):229–36.
 3. Kikkert M. Innate immune evasion by human respiratory RNA viruses. J 
Innate Immun. 2020;12(1):4–20.
 4. Sabbaghi A, Miri SM, Keshavarz M, Zargar M, Ghaemi A. Inactivation 
methods for whole influenza vaccine production. Rev Med Virol. 
2019;29(6):e2074.
 5. Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev 
Immunol. 2014;14(5):315–28.
 6. Matsukura S, Kokubu F, Kubo H, Tomita T, Tokunaga H, Kadokura M, et al. 
Expression of RANTES by normal airway epithelial cells after influenza 
virus A infection. Am J Resp Cell Mol. 1998;18(2):255–64.
 7. Provine NM, Binder B, FitzPatrick ME, Schuch A, Garner LC, Williamson 
KD, et al. Unique and common features of innate-like human Vδ2+ 
γδT cells and mucosal-associated invariant T cells. Front Immunol. 
2018;9:756.
 8. Kalyan S, Kabelitz D. Defining the nature of human γδ T cells: a 
biographical sketch of the highly empathetic. Cell Mol Immunol. 
2013;10(1):21–9.
 9. Li H, Xiang Z, Feng T, Li J, Liu Y, Fan Y, et al. Human Vγ9Vδ2-T cells effi-
ciently kill influenza virus-infected lung alveolar epithelial cells. Cell Mol 
Immunol. 2013;10(2):159–64. 
 10. Qin G, Mao H, Zheng J, Sia SF, Liu Y, Chan P-L, et al. Phosphoantigen-
expanded human γδ T cells display potent cytotoxicity against 
monocyte-derived macrophages infected with human and avian 
influenza viruses. J Infect. 2009;200(6):858–65. 
 11. Qin G, Liu Y, Zheng J, Ng IH, Xiang Z, Lam K-T, et al. Type 1 
responses of human Vγ9Vδ2 T cells to influenza A viruses. J Virol. 
2011;85(19):10109–16. 
 12. Jameson JM, Cruz J, Costanzo A, Terajima M, Ennis FA. A role for the 
mevalonate pathway in the induction of subtype cross-reactive immu-
nity to influenza A virus by human γδ T lymphocytes. Cell Immunol. 
2010;264(1):71–7.
 13. Carding SR, Allan W, Kyes S, Hayday A, Bottomly K, Doherty P. Late domi-
nance of the inflammatory process in murine influenza by gamma/
delta+ T cells. J Expe Med. 1990;172(4):1225–31. 
 14. Xi-zhi JG, Dash P, Crawford JC, Allen EK, Zamora AE, Boyd DF, et al. 
Lung γδ T cells mediate protective responses during neonatal influ-
enza infection that are associated with type 2 immunity. Immunity. 
2018;49(3):531–44.
 15. Davey MS, Willcox CR, Joyce SP, Ladell K, Kasatskaya SA, McLaren JE, 
et al. Clonal selection in the human Vδ1 T cell repertoire indicates 
γδ TCR-dependent adaptive immune surveillance. Nat Commun. 
2017;8(1):1–15.
 16. Chen Y-Q, Zheng L, Aldarouish M, Zhou Z-H, Pan N, Liu J-Q, et al. Wnt 
pathway activator TWS119 enhances the proliferation and cytol-
ytic activity of human γδT cells against colon cancer. Exp Cell Res. 
2018;362(1):63–71.
 17. Lalor SJ, McLoughlin RM. Memory γδ T cells–newly appreci-
ated protagonists in infection and immunity. Trends Immunol. 
2016;37(10):690–702. 
 18. Airoldi I, Bertaina A, Prigione I, Zorzoli A, Pagliara D, Cocco C, et al. 
γδ T-cell reconstitution after HLA-haploidentical hematopoietic 
transplantation depleted of TCR-αβ+/CD19+ lymphocytes. Blood. 
2015;125(15):2349–58.
 19. Ismaili J, Olislagers V, Poupot R, Fournié J-J, Goldman M. Human 
γδ T cells induce dendritic cell maturation. Clin Immunol. 
2002;103(3):296–302. 
 20. La Gruta NL, Kedzierska K, Stambas J, Doherty PC. A question of 
self-preservation: immunopathology in influenza virus infection. 
Immunol Cell Biol. 2007;85(2):85–92.
 21. Hufford MM, Richardson G, Zhou H, Manicassamy B, García-Sastre A, 
Enelow RI, et al. Influenza-infected neutrophils within the infected 
lungs act as antigen presenting cells for anti-viral CD8+ T cells. PLoS 
ONE. 2012;7(10):e46581.
 22. Cheung C, Poon L, Lau A, Luk W, Lau Y, Shortridge K, et al. Induction 
of proinflammatory cytokines in human macrophages by influenza 
A (H5N1) viruses: a mechanism for the unusual severity of human 
disease? Lancet. 2002;360(9348):1831–7. 
 23. Van Helden MJ, Zaiss DM, Sijts AJ. CCR2 defines a distinct population 
of NK cells and mediates their migration during influenza virus infec-
tion in mice. PLoS ONE. 2012;7(12):e52027. 
 24. Carlin LE, Hemann EA, Zacharias ZR, Heusel JW, Legge KL. Natural 
killer cell recruitment to the lung during influenza A virus infection is 
dependent on CXCR3, CCR5, and virus exposure dose. Front Immu-
nol. 2018;9:781.
 25. Grégoire C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier 
E, et al. The trafficking of natural killer cells. Immunol Rev. 
2007;220(1):169–82. 
 26. Du N, Zhou J, Lin X, Zhang Y, Yang X, Wang Y, et al. Differential activa-
tion of NK cells by influenza A pseudotype H5N1 and 1918 and 2009 
pandemic H1N1 viruses. J Virol. 2010;84(15):7822–31. 
 27. Mahooti M, Abdolalipour E, Salehzadeh A, Mohebbi SR, Gorji A, 
Ghaemi A. Immunomodulatory and prophylactic effects of Bifidobac-
terium bifidum probiotic strain on influenza infection in mice. World 
J Microbiol Biotechnol. 2019;35(6):91. 
 28. Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CG, Doer-
ing TA, et al. Innate lymphoid cells promote lung-tissue homeostasis 
after infection with influenza virus. Nat Immunol. 2011;12(11):1045.
 29. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. 
Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev 
Immunol. 2013;13(2):145–9.
 30. Shortman K, Liu Y-J. Mouse and human dendritic cell subtypes. Nat 
Rev Immunol. 2002;2(3):151–61.
 31. Liu Y-J, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plastic-
ity and cross-regulation. Nat immunol. 2001;2(7):585–9. 
 32. Ho AW, Prabhu N, Betts RJ, Ge MQ, Dai X, Hutchinson PE, et al. Lung 
CD103+ dendritic cells efficiently transport influenza virus to the 
lymph node and load viral antigen onto MHC class I for presentation 
to CD8 T cells. J Immunol. 2011;187(11):6011–21. 
 33. Helft J, Manicassamy B, Guermonprez P, Hashimoto D, Silvin A, Agudo 
J, et al. Cross-presenting CD103+ dendritic cells are protected from 
influenza virus infection. J Clin Invest. 2012;122(11):4037–47.
 34. Braciale TJ, Sun J, Kim TS. Regulating the adaptive immune response 
to respiratory virus infection. Nat Rev Immunol. 2012;12(4):295–305.
 35. Treiner E, Lantz O. CD1d-and MR1-restricted invariant T cells: of mice 
and men. Curr Opin Immunol. 2006;18(5):519–26.
 36. Van Wilgenburg B, Loh L, Chen Z, Pediongco TJ, Wang H, Shi M, et al. 
MAIT cells contribute to protection against lethal influenza infection 
in vivo. Nat Commun. 2018;9(1):1–9.
 37. Meierovics A, Yankelevich W-JC, Cowley SC. MAIT cells are critical 
for optimal mucosal immune responses during in vivo pulmonary 
bacterial infection. PNAS. 2013;110(33):E3119–28. 
 38. Wang H, D’Souza C, Lim XY, Kostenko L, Pediongco TJ, Eckle SB, et al. 
MAIT cells protect against pulmonary Legionella longbeachae infec-
tion. Nat Commun. 2018;9(1):1–15.
 39. Van Wilgenburg B, Scherwitzl I, Hutchinson EC, Leng T, Kurioka A, 
Kulicke C, et al. MAIT cells are activated during human viral infections. 
Nat Commun. 2016;7(1):1–11.
 40. Loh L, Wang Z, Sant S, Koutsakos M, Jegaskanda S, Corbett AJ, 
et al. Human mucosal-associated invariant T cells contribute to 
antiviral influenza immunity via IL-18-dependent activation. PNAS. 
2016;113(36):10133–8.
 41. McCullers JA. The co-pathogenesis of influenza viruses with bacteria 
in the lung. Nat Rev Microbiol. 2014;12(4):252–62. 
Page 16 of 18Sabbaghi et al. Virol J          (2020) 17:174 
 42. Rossjohn J, Pellicci DG, Patel O, Gapin L, Godfrey DI. Recognition of 
CD1d-restricted antigens by natural killer T cells. Nat Rev Immunol. 
2012;12(12):845–57.
 43. Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, Moody DB. The 
burgeoning family of unconventional T cells. Nat Immunol. 
2015;16(11):1114.
 44. Kok WL, Denney L, Benam K, Cole S, Clelland C, McMichael AJ, et al. 
Pivotal Advance: Invariant NKT cells reduce accumulation of inflamma-
tory monocytes in the lungs and decrease immune-pathology during 
severe influenza A virus infection. J Leukoc Biol. 2012;91(3):357–68.
 45. Ho LP, Denney L, Luhn K, Teoh D, Clelland C, McMichael AJ. Activation 
of invariant NKT cells enhances the innate immune response and 
improves the disease course in influenza A virus infection. Eur J Immu-
nol. 2008;38(7):1913–22.
 46. Guillonneau C, Mintern JD, Hubert F-X, Hurt AC, Besra GS, Porcelli S, 
et al. Combined NKT cell activation and influenza virus vaccination 
boosts memory CTL generation and protective immunity. PNAS. 
2009;106(9):3330–5.
 47. Youn H-J, Ko S-Y, Lee K-A, Ko H-J, Lee Y-S, Fujihashi K, et al. A sin-
gle intranasal immunization with inactivated influenza virus and 
α-galactosylceramide induces long-term protective immunity 
without redirecting antigen to the central nervous system. Vaccine. 
2007;25(28):5189–98.
 48. Kreijtz J, Fouchier R, Rimmelzwaan G. Immune responses to influenza 
virus infection. Virus Res. 2011;162(1–2):19–30.
 49. Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding 
H, et al. Broadly neutralizing human antibody that recognizes the 
receptor-binding pocket of influenza virus hemagglutinin. PNAS. 
2011;108(34):14216–21.
 50. Mozdzanowska K, Maiese K, Furchner M, Gerhard W. Treatment of 
influenza virus-infected SCID mice with nonneutralizing antibodies 
specific for the transmembrane proteins matrix 2 and neuraminidase 
reduces the pulmonary virus titer but fails to clear the infection. Virol-
ogy. 1999;254(1):138–46.
 51. Nüssing S, Sant S, Koutsakos M, Subbarao K, Nguyen TH, Kedzier-
ska K. Innate and adaptive T cells in influenza disease. Front Med. 
2018;12(1):34–47.
 52. Lamb J, Woody J, Hartzman R, Eckels D. In vitro influenza virus-specific 
antibody production in man: antigen-specific and HLA-restricted 
induction of helper activity mediated by cloned human T lymphocytes. 
J Immunol. 1982;129(4):1465–70.
 53. Surls J, Nazarov-Stoica C, Kehl M, Casares S, Brumeanu T-D. Differential 
effect of CD4+ Foxp3+ T-regulatory cells on the B and T helper cell 
responses to influenza virus vaccination. Vaccine. 2010;28(45):7319–30.
 54. Chen H, Ji X, Cui L, Zhang J, He W. Characterization of complementary 
determinant region 3δ in human MutS homologue 2-specific γδ T cells. 
Scand J Immunol. 2015;81(2):121–8.
 55. Gong Q, Wang C, Zhang W, Iqbal J, Hu Y, Greiner TC, et al. Assessment 
of T-cell receptor repertoire and clonal expansion in peripheral T-cell 
lymphoma using RNA-seq data. Sci Rep. 2017;7(1):1–10.
 56. Hatano S, Tun X, Noguchi N, Yue D, Yamada H, Sun X, et al. Develop-
ment of a new monoclonal antibody specific to mouse Vγ6 chain. Life 
Sci Alliance. 2019;2(3):e201900363.
 57. Weitkamp J-H, Rosen MJ, Zhao Z, Koyama T, Geem D, Denning TL, et al. 
Small intestinal intraepithelial TCRγδ+ T lymphocytes are present in 
the premature intestine but selectively reduced in surgical necrotizing 
enterocolitis. PLoS ONE. 2014;9(6):e99042. 
 58. Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR. Human γδ T cells: 
a nonredundant system in the immune-surveillance against cancer. 
Trends Immunol. 2002;23(1):14–8.
 59. Zhao Y, Lin L, Xiao Z, Li M, Wu X, Li W, et al. Protective role of γδ T cells 
in different pathogen infections and its potential clinical application. J 
Immunol Res. 2018;2018:5081634.
 60. Dong P, Ju X, Yan Y, Zhang S, Cai M, Wang H, et al. γδ T cells provide 
protective function in highly pathogenic avian H5N1 influenza A virus 
infection. Front Immunol. 2018;9:2812.
 61. Sant S, Jenkins MR, Dash P, Watson KA, Wang Z, Pizzolla A, et al. Human 
γδ T-cell receptor repertoire is shaped by influenza viruses, age and 
tissue compartmentalisation. Clin Trans Immunol. 2019;8(9):e1079. 
 62. Ribeiro ST, Ribot JC, Silva-Santos B. Five layers of receptor signalling in 
γδ T cell differentiation and activation. Front Immunol. 2015;6:15.
 63. Nakamizo S, Egawa G, Tomura M, Sakai S, Tsuchiya S, Kitoh A, et al. Der-
mal Vc4 cd T cells possess a migratory potency to the draining lymph 
nodes and modulate CD8 T-cell activity through TNF-a production. J 
Invest Dermatol. 2015;135:1007–15.
 64. Paul S, Lal G. Regulatory and effector functions of gamma–delta (γδ) 
T cells and their therapeutic potential in adoptive cellular therapy for 
cancer. Int J Cancer. 2016;139(5):976–85.
 65. Rezende RM, Lanser AJ, Rubino S, Kuhn C, Skillin N, Moreira TG, et al. 
γδ T cells control humoral immune response by inducing T follicular 
helper cell differentiation. Nat Commun. 2018;9(1):1–13.
 66. Caccamo N, Battistini L, Bonneville M, Poccia F, Fournié JJ, Meraviglia 
S, et al. CXCR5 identifies a subset of Vγ9Vδ2 T cells which secrete 
IL-4 and IL-10 and help B cells for antibody production. J Immunol. 
2006;177(8):5290–5.
 67. Inoue SI, Niikura M, Asahi H, Kawakami Y, Kobayashi F. γδ T cells modu-
late humoral immunity against Plasmodium berghei infection. Immunol-
ogy. 2018;155(4):519–32.
 68. Cuthbert RJ, Watad A, Fragkakis EM, Dunsmuir R, Loughenbury P, Khan 
A, et al. Evidence that tissue resident human enthesis γδT-cells can pro-
duce IL-17A independently of IL-23R transcript expression. Ann Rheum 
Dis. 2019;78(11):1559–65.
 69. Li-da Sun SQ, Wang Y, Pang G-J, Zha X-Y, Liu T-L, Zhao H-L, et al. 
Vγ4+ T cells: a novel IL-17-producing γδ T subsets during the early 
phase of chlamydial airway infection in mice. Mediat Inflamm. 
2018;2018:6265746.
 70. Braun RK, Ferrick C, Neubauer P, Sjoding M, Sterner-Kock A, Kock M, 
et al. IL-17 producing γδ T cells are required for a controlled inflam-
matory response after bleomycin-induced lung injury. Inflammation. 
2008;31(3):167–79.
 71. Kelly MN, Kolls JK, Happel K, Schwartzman JD, Schwarzenberger P, 
Combe C, et al. Interleukin-17/interleukin-17 receptor-mediated 
signaling is important for generation of an optimal polymorphonu-
clear response against Toxoplasma gondii infection. Infect Immun. 
2005;73(1):617–21.
 72. Ye P, Garvey PB, Zhang P, Nelson S, Bagby G, Summer WR, et al. Interleu-
kin-17 and lung host defense against Klebsiella pneumoniae infection. 
Am J Resp Cell Mol. 2001;25(3):335–40.
 73. Bi H-S, Liu Z-F, Cui Y. Pathogenesis of innate immunity and adaptive 
immunity in the mouse model of experimental autoimmune uveitis. J 
Chin Med Assoc. 2015;78(5):276–82.
 74. Pasman L, Kasper DL. Building conventions for unconventional lympho-
cytes. Immunol Rev. 2017;279(1):52–62.
 75. Wang T, Scully E, Yin Z, Kim JH, Wang S, Yan J, et al. IFN-γ-producing 
γδ T cells help control murine West Nile virus infection. J Immunol. 
2003;171(5):2524–31.
 76. Boullier S, Dadaglio G, Lafeuillade A, Debord T, Gougeon M-L. V delta 1 
T cells expanded in the blood throughout HIV infection display a cyto-
toxic activity and are primed for TNF-alpha and IFN-gamma production 
but are not selected in lymph nodes. J Immunol. 1997;159(7):3629–37.
 77. Fausther-Bovendo H, Wauquier N, Cherfils-Vicini J, Cremer I, Debré P, 
Vieillard V. NKG2C is a major triggering receptor involved in the Vδ1 
T cell-mediated cytotoxicity against HIV-infected CD4 T cells. Aids. 
2008;22(2):217–26.
 78. He X, Liang H, Hong K, Li H, Peng H, Zhao Y, et al. The potential role of 
CD16+ Vγ2Vδ2 T cell-mediated antibody-dependent cell-mediated 
cytotoxicity in control of HIV type 1 disease. AIDS Res Hum Retroviruses. 
2013;29(12):1562–70. 
 79. Xiang Z, Liu Y, Zheng J, Liu M, Lv A, Gao Y, et al. Targeted activation 
of human Vγ9Vδ2-T cells controls Epstein–Barr virus-induced B cell 
lymphoproliferative disease. Cancer Cell. 2014;26(4):565–76.
 80. Cimini E, Sacchi A, De Minicis S, Bordoni V, Casetti R, Grassi G, et al. Vδ2 
T-cells Kill ZIKV-infected cells by NKG2D-mediated cytotoxicity. Microor-
ganisms. 2019;7(9):350.
 81. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, 
Herrmann T. Activation of Vγ9Vδ2 T cells by NKG2D. J Immunol. 
2005;175(4):2144–51.
 82. Maloy KJ, Odermatt B, Hengartner H, Zinkernagel RM. Interferon 
gamma-producing gammadelta T cell-dependent antibody isotype 
switching in the absence of germinal center formation during virus 
infection. PNAS USA. 1998;95(3):1160–5.
Page 17 of 18Sabbaghi et al. Virol J          (2020) 17:174  
 83. Selin LK, Santolucito PA, Pinto AK, Szomolanyi-Tsuda E, Welsh RM. Innate 
immunity to viruses: control of vaccinia virus infection by γδ T cells. J 
Immunol. 2001;166(11):6784–94.
 84. Kodukula P, Liu T, Van Rooijen N, Jager MJ, Hendricks RL. Macrophage 
control of herpes simplex virus type 1 replication in the peripheral 
nervous system. J Immunol. 1999;162(5):2895–905.
 85. Ninomiya T, Takimoto H, Matsuzaki G, Hamano S, Yoshida H, Yoshikai Y, 
et al. Vgamma1+ gammadelta T cells play protective roles at an early 
phase of murine cytomegalovirus infection through production of 
interferon-gamma. Immunology. 2000;99(2):187–94.
 86. Agrati C, Alonzi T, De Santis R, Castilletti C, Abbate I, Capobianchi 
MR, et al. Activation of Vγ9Vδ2 T cells by non-peptidic antigens 
induces the inhibition of subgenomic HCV replication. Int Immunol. 
2006;18(1):11–8.
 87. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by 
the innate and adaptive immuneresponse. Annu Rev Immunol. 
2001;19(1):65–91.
 88. Frese M, Schwärzle V, Barth K, Krieger N, Lohmann V, Mihm S, et al. 
Interferon-γ inhibits replication of subgenomic and genomic hepatitis 
C virus RNAs. Hepatol. 2002;35(3):694–703.
 89. Karupiah G, Xie Q-W, Buller R, Nathan C, Duarte C, MacMicking JD. 
Inhibition of viral replication by interferon-gamma-induced nitric oxide 
synthase. Science. 1993;261(5127):1445–8.
 90. Couzi L, Pitard V, Sicard X, Garrigue I, Hawchar O, Merville P, et al. 
Antibody-dependent anti-cytomegalovirus activity of human γδ T cells 
expressing CD16 (FcγRIIIa). Blood. 2012;119(6):1418–27.
 91. Poccia F, Battistini L, Cipriani B, Mancino G, Martini F, Gougeon ML, 
et al. Phosphoantigen-reactive Vγ9Vδ2 T lymphocytes suppress in vitro 
human immunodeficiency virus type 1 replication by cell-released 
antiviral factors including CC chemokines. J Infect. 1999;180(3):858–61.
 92. Hudspeth K, Fogli M, Correia DV, Mikulak J, Roberto A, Della Bella S, 
et al. Engagement of NKp30 on Vδ1 T cells induces the production 
of CCL3, CCL4, and CCL5 and suppresses HIV-1 replication. Blood. 
2012;119(17):4013–6.
 93. Tuero I, Venzon D, Robert-Guroff M. Mucosal and systemic γδ+ T cells 
associated with control of simian immunodeficiency virus infection. J 
Immunol. 2016;197(12):4686–95.
 94. Poccia F, Agrati C, Castilletti C, Bordi L, Gioia C, Horejsh D, et al. Anti-
severe acute respiratory syndrome coronavirus immune responses: the 
role played by Vγ9Vδ2 T cells. J Infect. 2006;193(9):1244–9.
 95. Tsai C-Y, Liong KH, Gunalan MG, Li N, Lim DSL, Fisher DA, et al. Type I 
IFNs and IL-18 regulate the antiviral response of primary human γδ 
T cells against dendritic cells infected with dengue virus. J Immunol. 
2015;194(8):3890–900.
 96. Halary F, Pitard V, Dlubek D, Krzysiek R, de La Salle H, Merville P, et al. 
Shared reactivity of Vδ2neg γδ T cells against cytomegalovirus-
infected cells and tumor intestinal epithelial cells. J Exp Med. 
2005;201(10):1567–78.
 97. Worku S, Gorse GJ, Belshe RB, Hoft DF. Canarypox vaccines induce 
antigen-specific human γδ T cells capable of interferon-γ production. J 
Infect. 2001;184(5):525–32.
 98. Maccario R, Comoli P, Percivalle E, Montagna D, Locatelli F, Gerna G. 
Herpes simplex virus-specific human cytotoxic T-cell colonies express-
ing either gamma delta or alpha beta T-cell receptor: role of accessory 
molecules on HLA-unrestricted killing of virus-infected targets. Immu-
nology. 1995;85(1):49.
 99. Huber SA, Graveline D, Newell MK, Born WK, O’Brien RL. Vγ1+ T cells 
suppress and Vγ4+ T cells promote susceptibility to coxsackievirus 
B3-induced myocarditis in mice. J Immunol. 2000;165(8):4174–81.
 100. Born WK, Lahn M, Takeda K, Kanehiro A, O’Brien RL, Gelfand EW. Role of 
gammadelta T cells in protecting normal airway function. Respir Res. 
2000;1(3):6.
 101. Cheng M, Hu S. Lung-resident γδ T cells and their roles in lung diseases. 
Immunol. 2017;151(4):375–84.
 102. Kirby AC, Newton DJ, Carding SR, Kaye PM. Evidence for the involve-
ment of lung-specific γδ T cell subsets in local responses to Streptococ-
cus pneumoniae infection. Eur J Immunol. 2007;37(12):3404–13.
 103. Huang H, Saravia J, You D, Shaw AJ, Cormier SA. Impaired gamma 
delta T cell-derived IL-17A and inflammasome activation during 
early respiratory syncytial virus infection in infants. Immunol Cell Biol. 
2015;93(2):126–35.
 104. Dodd J, Riffault S, Kodituwakku JS, Hayday AC, Openshaw PJ. Pulmonary 
Vγ4+ γδ T cells have proinflammatory and antiviral effects in viral lung 
disease. J Immunol. 2009;182(2):1174–81.
 105. Schwaiger T, Sehl J, Karte C, Schäfer A, Hühr J, Mettenleiter TC, et al. 
Experimental H1N1pdm09 infection in pigs mimics human seasonal 
influenza infections. PLoS ONE. 2019;14(9):e0222943.
 106. Palomino-Segura M, Latino I, Farsakoglu Y, Gonzalez SF. Early production 
of IL-17A by γδ T cells in the trachea promotes viral clearance during 
influenza infection in mice. Eur J Immunol. 2020;50(1):97–109.
 107. Luukkainen A, Puan KJ, Yusof N, Lee B, Tan KS, Liu J, et al. A co-culture 
model of PBMC and stem cell derived human nasal epithelium reveals 
rapid activation of NK and innate T cells upon Influenza A virus infec-
tion of the nasal epithelium. Front immunol. 2018;9:2514.
 108. Goldberg EL, Molony RD, Kudo E, Sidorov S, Kong Y, Dixit VD, et al. 
Ketogenic diet activates protective γδ T cell responses against influenza 
virus infection. Sci Immunol. 2019;4(41):e2026.
 109. Ivanov S, Renneson J, Fontaine J, Barthelemy A, Paget C, Fernandez EM, 
et al. Interleukin-22 reduces lung inflammation during influenza A virus 
infection and protects against secondary bacterial infection. J Virol. 
2013;87(12):6911–24.
 110. Moser EK, Sun J, Kim TS, Braciale TJ. IL-21R signaling suppresses IL-17+ 
gamma delta T cell responses and production of IL-17 related cytokines 
in the lung at steady state and after influenza A virus infection. PLoS 
ONE. 2015;10(4):e0120169.
 111. Zhao P, Hou L, Farley K, Sundrud MS, Remold-OˈDonnell E. SerpinB1 
regulates homeostatic expansion of IL-17+ γδ and CD4+ Th17 cells. J 
Leukoc Biol. 2014;95(3):521–30.
 112. Li W, Moltedo B, Moran TM. Type I interferon induction during influenza 
virus infection increases susceptibility to secondary Streptococcus 
pneumoniae infection by negative regulation of γδ T cells. J Virol. 
2012;86(22):12304–12.
 113. Cao J, Wang D, Xu F, Gong Y, Wang H, Song Z, et al. Activation of IL-27 
signalling promotes development of postinfluenza pneumococcal 
pneumonia. EMBO Mol Med. 2014;6(1):120–40.
 114. Hoq MM, Suzutani T, Toyoda T, Horiike G, Yoshida I, Azuma M. Role 
of gamma delta TCR+ lymphocytes in the augmented resistance of 
trehalose 6, 6′-dimycolate-treated mice to influenza virus infection. J 
Gen Virol. 1997;78(7):1597–603.
 115. Xue C, Wen M, Bao L, Li H, Li F, Liu M, et al. Vγ4+ γδT cells aggravate 
severe H1N1 influenza virus infection-induced acute pulmonary immu-
nopathological injury via secreting interleukin-17A. Front Immunol. 
2017;8:1054. 
 116. Qin G, Liu Y, Zheng J, Xiang Z, Ng IH, Malik Peiris J, et al. Phenotypic and 
functional characterization of human γδ T-cell subsets in response to 
influenza A viruses. J Infect. 2012;205(11):1646–53.
 117. Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, 
et al. Live and inactivated influenza vaccines induce similar humoral 
responses, but only live vaccines induce diverse T-cell responses in 
young children. J Infect. 2011;204(6):845–53.
 118. Stervbo U, Pohlmann D, Baron U, Bozzetti C, Jürchott K, Mälzer JN, et al. 
Age dependent differences in the kinetics of γδ T cells after influenza 
vaccination. PLoS ONE. 2017;12(7):e0181161.
 119. Horvath KM, Brighton LE, Herbst M, Noah TL, Jaspers I. Live attenu-
ated influenza virus (LAIV) induces different mucosal T cell function in 
nonsmokers and smokers. Clin Immunol. 2012;142(3):232–6.
 120. Hong M, Gu B, Madison M, Landers C, Tung H, Kim M, et al. Protective 
role of γδ T cells in cigarette smoke and influenza infection. Mucosal 
Immunol. 2018;11(3):894–908.
 121. Costanzo AE, Taylor KR, Dutt S, Han PP, Fujioka K, Jameson JM. Obesity 
impairs γδ T cell homeostasis and antiviral function in humans. PLoS 
ONE. 2015;10(3):e0120918.
 122. Krementsov DN, Case LK, Dienz O, Raza A, Fang Q, Ather JL, et al. 
Genetic variation in chromosome Y regulates susceptibility to influenza 
A virus infection. PNAS. 2017;114(13):3491–6.
 123. Tu W, Zheng J, Liu Y, Sia SF, Liu M, Qin G, et al. The aminobisphospho-
nate pamidronate controls influenza pathogenesis by expanding a γδ T 
cell population in humanized mice. J Exp Med. 2011;208(7):1511–22.
 124. Poonia B, Pauza CD. Gamma delta T cells from HIV+ donors can be 
expanded in vitro by zoledronate/interleukin-2 to become cytotoxic 
effectors for antibody-dependent cellular cytotoxicity. Cytotherapy. 
2012;14(2):173–81.
Page 18 of 18Sabbaghi et al. Virol J          (2020) 17:174 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 125. Agrati C, Castilletti C, Cimini E, Romanelli A, Lapa D, Quartu S, et al. Anti-
viral activity of human Vdelta2 T-cells against WNV includes both cytol-
ytic and non-cytolytic mechanisms. New Microbiol. 2016;39:139–42.
 126. Lopez RD. Human γδ-T cells in adoptive immunotherapy of malignant 
and infectious diseases. Immunol Res. 2002;26(1–3):207–21.
 127. Nantz MP, Rowe CA, Muller C, Creasy R, Colee J, Khoo C, et al. Consump-
tion of cranberry polyphenols enhances human γδ-T cell proliferation 
and reduces the number of symptoms associated with colds and 
influenza: a randomized, placebo-controlled intervention study. Nutr J. 
2013;12(1):161.
 128. Nantz MP, Rowe CA, Muller CE, Creasy RA, Stanilka JM, Percival SS. 
Supplementation with aged garlic extract improves both NK and γδ-T 
cell function and reduces the severity of cold and flu symptoms: a 
randomized, double-blind, placebo-controlled nutrition intervention. 
Clin Nutr. 2012;31(3):337–44.
 129. Bukowski JF, Percival SS. L-theanine intervention enhances human γδ T 
lymphocyte function. Nutr Rev. 2008;66(2):96–102.
 130. Percival SS. Aged garlic extract modifies human immunity. Nutr J. 
2016;146(2):433S-S436.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
